Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Using Radiomics for Risk Stratification: Where We Need to Go.

Literature DB >> 34726541

Using Radiomics for Risk Stratification: Where We Need to Go.

William Hsu¹, Jae Ho Sohn¹.

Abstract

Entities: Chemical

Mesh：

Year: 2021 PMID： 34726541 PMCID： PMC8805519 DOI： 10.1148/radiol.2021212085

Source DB: PubMed Journal: Radiology ISSN： 0033-8419 Impact factor: 29.146

Keyword Cloud
References

× No keyword cloud information.

7 in total

1. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.

Authors: Sarah A Mattonen; David A Palma; Carol Johnson; Alexander V Louie; Mark Landis; George Rodrigues; Ian Chan; Roya Etemad-Rezai; Timothy P C Yeung; Suresh Senan; Aaron D Ward
Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-29 Impact factor: 7.038

Review 2. Radiomics: the bridge between medical imaging and personalized medicine.

Authors: Philippe Lambin; Ralph T H Leijenaar; Timo M Deist; Jurgen Peerlings; Evelyn E C de Jong; Janita van Timmeren; Sebastian Sanduleanu; Ruben T H M Larue; Aniek J G Even; Arthur Jochems; Yvonka van Wijk; Henry Woodruff; Johan van Soest; Tim Lustberg; Erik Roelofs; Wouter van Elmpt; Andre Dekker; Felix M Mottaghy; Joachim E Wildberger; Sean Walsh
Journal: Nat Rev Clin Oncol Date: 2017-10-04 Impact factor: 66.675

3. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer.

Authors: Yanqi Huang; Zaiyi Liu; Lan He; Xin Chen; Dan Pan; Zelan Ma; Cuishan Liang; Jie Tian; Changhong Liang
Journal: Radiology Date: 2016-06-27 Impact factor: 11.105

Using Radiomics for Risk Stratification: Where We Need to Go.

1. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.

Review 2. Radiomics: the bridge between medical imaging and personalized medicine.

3. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer.

4. Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer.

Review 5. Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.

6. Quantifying the added value of new biomarkers: how and how not.

Review 7. The Biological Meaning of Radiomic Features.